All In Biotech

Drug Trial Radar · NCT07038447

A Study of KITE-363 in Participants With Refractory Autoimmune Diseases

A Phase 1 Open-label, Multiregional, Multicenter, Basket Study Evaluating the Safety and Efficacy of KITE-363, an Autologous Anti-CD19/CD20 CAR T-cell Therapy in Participants With Refractory Autoimmune Diseases

Last checked: Nov 19, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitation

Status

Enrolling by invitation

Enrollment

52

Planned (sponsor's estimate)

Start

Jul 2, 2025

Primary completion

Sep 2030

Study completion Sep 2030

Sponsor

Lead sponsor
Kite, A Gilead CompanyGilead Sciences (GILD)
Sponsor type
Industry
First posted
Jun 26, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will have two Phases: Phase 1a and Phase 1b. The goal of this clinical study is to learn more about the study drug KITE-363, to establish dosing, tolerability, safety, and preliminary efficacy of KITE-363 in participants with refractory autoimmune diseases. The primary objectives of this study are: Phase 1a: To evaluate the safety and tolerability of KITE-363 in participants with autoimmune disease. To determine the recommended dose for Phase 1b. Phase 1b: To evaluate the safety and efficacy of KITE-363 in participants with autoimmune disease.

Conditions

  • Systemic Lupus Erythematosus
  • Lupus Nephritis
  • Systemic Sclerosis
  • Idiopathic Inflammatory Myopathy

Interventions

  • KITE-363Biological

    A single infusion of CAR-transduced autologous T cells administered intravenously

  • FludarabineDrug

    Administered intravenously

  • CyclophosphamideDrug

    Administered intravenously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1a: Percentage of Participants Experiencing Adverse Events Defined as Dose-limiting Toxicities (DLTs) After the Infusion of KITE-363Time frame: Up to 2 years
  2. Phase 1b: All Cohorts Percentage of Participants Experiencing Treatment-emergent Adverse Event (TEAEs)Time frame: Up to 2 years
  3. Phase 1b: Systemic lupus erythematosus (SLE): Proportion of participants meeting DORIS remission and Lupus low Disease Activity State (LLDAS) criteria at Month 6Time frame: Month 6
  4. Phase 1b: Lupus Nephritis (LN): Proportion of Participants Meeting DORIS RemissionTime frame: Month 6
  5. Phase 1b: LN: Proportion of Participants Achieving a Complete Renal Response at Month 6Time frame: Month 6
  6. Phase 1b: Systemic Sclerosis (SSc) Cohort: Proportion of Participants With Improvement in Disease Activity by the Revised Combined Response Index in Diffuse Cutaneous Systemic Sclerosis (rCRISS) at Month 6Time frame: Month 6
  7. Phase 1b: Idiopathic Inflammatory Myopathy (IIM): Proportions of Participants Meeting European League Against Rheumatism (EULAR)-American College of Rheumatology (ACR) Moderate and Major response 2016 Criteria in Total Improvement Score (TIS) at Month 6Time frame: Month 6

Locations

10 sites in 4 countries. Site status is shown where the registry gives one.

  • City of Hope

    Duarte, California

  • Stanford University

    Stanford, California

  • Tampa General Hospital Cancer Institute

    Tampa, Florida

  • Icahn School of Medicine at Mount Sinai

    New York, New York

  • Concord Repatriation General Hospital

    Syndey, New South Wales, Australia

  • St Vincent's Hospital

    Fitzroy, Victoria, Australia

  • Jewish General Hospital

    Montreal, Canada

  • The Ottawa Hospital, General Campus

    Ottawa, Canada

  • Seoul National University

    Seoul, South Korea

  • Asan Medical Center

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.